Citigroup Issues Positive Forecast for Biomea Fusion (NASDAQ:BMEA) Stock Price

Biomea Fusion (NASDAQ:BMEA) had its price target increased by Citigroup from $6.00 to $7.00 in a report published on Friday,Benzinga reports. Citigroup currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biomea Fusion in a research report on Wednesday, January 21st. D. Boral Capital restated a “buy” rating and issued a $12.00 price objective on shares of Biomea Fusion in a report on Wednesday. Finally, Rodman & Renshaw began coverage on Biomea Fusion in a research report on Tuesday, January 13th. They set a “buy” rating and a $8.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.75.

Biomea Fusion Trading Down 3.6%

Shares of Biomea Fusion stock opened at $1.32 on Friday. Biomea Fusion has a 12-month low of $0.87 and a 12-month high of $3.08. The company has a market cap of $95.44 million, a P/E ratio of -1.01 and a beta of -0.20. The company’s fifty day simple moving average is $1.29 and its two-hundred day simple moving average is $1.42.

Institutional Trading of Biomea Fusion

Hedge funds have recently modified their holdings of the business. AQR Capital Management LLC increased its stake in shares of Biomea Fusion by 670.5% in the 1st quarter. AQR Capital Management LLC now owns 264,028 shares of the company’s stock worth $562,000 after acquiring an additional 229,763 shares in the last quarter. XTX Topco Ltd purchased a new position in Biomea Fusion during the 2nd quarter valued at about $270,000. Scotia Capital Inc. bought a new stake in Biomea Fusion during the second quarter worth about $459,000. Aisling Capital Management LP boosted its stake in Biomea Fusion by 156.5% during the second quarter. Aisling Capital Management LP now owns 2,048,757 shares of the company’s stock worth $3,688,000 after acquiring an additional 1,250,000 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its holdings in Biomea Fusion by 99.2% in the second quarter. Bridgeway Capital Management LLC now owns 70,300 shares of the company’s stock worth $127,000 after purchasing an additional 35,000 shares during the period. Institutional investors own 96.72% of the company’s stock.

More Biomea Fusion News

Here are the key news stories impacting Biomea Fusion this week:

• Positive Sentiment: Citigroup raised its price target on BMEA from $6.00 to $7.00 and reiterated a “buy” rating — the new target implies substantial upside versus the current share level. Read More.
• Positive Sentiment: HC Wainwright published a set of updated EPS forecasts (Q1–Q4 2026 and FY2026–FY2028) and materially lifted its multi-year loss estimates (FY2026 from ($1.37) to ($0.57); FY2027 to ($0.64); FY2028 to ($0.78)), signaling the firm expects smaller losses and improving financials over time. The report also lists per-quarter EPS expectations for 2026. Read More.
• Positive Sentiment: D. Boral Capital initiated/maintained a buy rating on Biomea Fusion, adding another independent positive analyst voice. Read More.
• Positive Sentiment: Recent coverage highlights continued strong analyst sentiment driven by encouraging diabetes trial results, supporting the investment case for BMEA’s pipeline upside. Read More.
• Neutral Sentiment: Despite the positive analyst action and trial commentary, the stock is trading lower today — likely a short-term reaction (profit-taking, low liquidity, or risk-off flows common in small-cap biotech) rather than a reversal of analyst views. Monitor trading volume and upcoming clinical or corporate catalysts for signs of follow-through.

Biomea Fusion Company Profile

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.